Abstract
Factors contributing to increased risk for Alzheimer's disease (AD) include age, sex,
genes, and family history of AD. Several risk factors for AD are endogenous; however,
accumulating evidence implicates modifiable risk factors in the pathogenesis of AD.
Although the continued task of identifying new genes will be critical to learning
more about the disease, several research findings suggest that potentially alterable
environmental factors influence genetic contributions, providing targets for disease
prevention and treatment. Here, we review midlife risk factors for AD, and address
the potential for therapeutic intervention in midlife.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- World Alzheimer Report.2009
- Prevalence of dementia in the United States: the aging, demographics, and memory study.Neuroepidemiology. 2007; 29: 125-132
- Prevalence of dementia in the elderly in Europe.Eur Neuropsychopharmacol. 2005; 15: 463-471
- Age, neuropathology, and dementia.N Engl J Med. 2009; 360: 2302-2309
- Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship.J Neuropathol Exp Neurol. 2009; 68: 1-14
- Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.Neurobiol Aging. 2009; 30: 1026-1036
- Frequency of stages of Alzheimer-related lesions in different age categories.Neurobiol Aging. 1997; 18: 351-357
- Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.Science. 1993; 261: 921-923
- APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.BMC Neurol. 2008; 8: 9
- Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?.Ann Hum Genet. 1999; 63: 301-310
- Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.N Engl J Med. 2009; 361: 255-263
- Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.N Engl J Med. 1996; 334: 752-758
- Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory.Neurosci Lett. 2006; 396: 23-27
- Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele.Neurology. 2006; 67: 1221-1224
- Patterns of brain activation in people at risk for Alzheimer's disease.N Engl J Med. 2000; 343: 450-456
- IC-P-043 functional perfusion MRI shows decreased hippocampal signal with normal aging in ApoE4 carriers.Alzheimers Demen. 2006; 2: S671-S672
- Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.Proc Natl Acad Sci USA. 2009; 106: 6820-6825
- Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers.Neuroreport. 2005; 16: 1369-1372
- Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD?.Neurology. 2006; 66: 1029-1033
- Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.Nat Genet. 2009; 41: 1094-1099
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.Nat Genet. 2009; 41: 1088-1093
- Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.Nat Rev Neurosci. 2008; 9: 768-778
- Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders.Arch Neurol. 1991; 48: 269-273
- Risk of dementia among white and African American relatives of patients with Alzheimer disease.JAMA. 2002; 287: 329-336
- Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease.Arch Neurol. 2008; 65: 373-378
- Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease.Arch Neurol. 1998; 55: 810-816
- Antecedent biomarkers of Alzheimer's disease: the adult children study.J Geriatr Psychiatry Neurol. 2005; 18: 242-244
- Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.J Geriatr Psychiatry Neurol. 2005; 18: 245-249
- Effect of parental family history of Alzheimer's disease on serial position profiles.Alzheimers Demen. 2008; 4: 285-290
- The influence of parental history of Alzheimer's disease and apolipoprotein Eɛ4 on the BOLD signal during recognition memory.Brain. 2008;
- The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.J Neurosci. 2006; 26: 6069-6076
- Johnson SC: fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease.Neuropsychologia. 2007;
- Effect of Alzheimer disease risk on brain function during self-appraisal in healthy middle-aged adults.Arch Gen Psychiatry. 2007; 64: 1163-1171
- Apolipoprotein E genotype affects neural activation in the mesial temporal lobe of a cognitively normal cohort with familial history of AD.in: International Neuropsychological Society annual meeting: 2004, Baltimore2004
- Familial risk for Alzheimer's disease alters fMRI activation patterns.Brain. 2006; 129: 1229-1239
- Cerebral perfusion and oxygenation differences in Alzheimer's disease risk.Neurobiol Aging. 2008;
Bendlin BB, Ries ML, Canu E, et al. White matter is altered with parental family history of Alzheimer's disease. Alzheimer Demen; in press, doi:10.1016/j.jalz.2009.11.003.
- Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease.Neurology. 2008;
- Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.Proc Natl Acad Sci USA. 2007; 104: 19067-19072
- Sex, hormones, and Alzheimer's disease.J Gerontol A Biol Sci Med Sci. 2005; 60: 736-743
- Post-menopausal estrogen deprivation and Alzheimer's disease.Exp Gerontol. 2000; 35: 503-511
- Endogenous estrogen levels and Alzheimer's disease among postmenopausal women.Neurology. 2000; 54: 833-837
- Estrogens influence growth, maturation, and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line.Adv Exp Med Biol. 1997; 429: 261-271
- Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro.Biochem Biophys Res Commun. 2007; 359: 697-702
- Estradiol prevents amyloid-beta peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor.Neuroscience. 2003; 121: 917-926
- Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice.Endocrinology. 2008; 149: 2607-2611
- Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice.J Neurosci. 2007; 27: 13357-13365
- 17Alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice.J Alzheimers Dis. 2002; 4: 449-457
- Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain.Exp Gerontol. 2000; 35: 1317-1325
- Disruption of estrogen receptor beta in mice brain results in pathological alterations resembling Alzheimer disease.Acta Pharmacol Sin. 2004; 25: 452-457
- Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination.Brain. 2005; 128: 1613-1621
- Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease.Endocrinology. 2005; 146: 2774-2781
- Lack of protective effect of estrogens on cerebral A-beta levels in intact female and male APP transgenic mice.Drug Dev Res. 2006; 66: 136-141
- Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.JAMA. 2002; 288: 2123-2129
- A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging.Neurology. 1997; 48: 1517-1521
- Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.Lancet. 1996; 348: 429-432
- Estrogen replacement therapy and risk of Alzheimer disease.Arch Intern Med. 1996; 156: 2213-2217
- Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.JAMA. 2004; 291: 2959-2968
- Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.Climacteric. 2009; : 1-12
- Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey.J Obstet Gynaecol Can. 2004; 26: 967-973
- The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000–2002).J Womens Health (Larchmt). 2004; 13: 975-985
- Patients’ and clinicians’ attitudes after the Women's Health Initiative study.Menopause. 2004; 11: 57-61
- Hormones down under: hormone therapy use after the Women's Health Initiative.Aust N Z J Obstet Gynaecol. 2006; 46: 330-335
- How the Women's Health Initiative (WHI) influenced physicians’ practice and attitudes.J Gen Intern Med. 2007; 22: 1311-1316
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Pitfalls of the WHIs: Women's Health Initiative.Ann NY Acad Sci. 2006; 1092: 331-340
- Is the WHI relevant to HRT started in the perimenopause?.Endocrine. 2004; 24: 195-202
- WHI clinical trial revisit: imprecise scientific methodology disqualifies the study's outcomes.Am J Obstet Gynecol. 2005; 193 (discussion 1605-1596): 1599-1604
- Issues to debate on the Women's Health Initiative (WHI) study.Hum Reprod. 2004; 19: 8-13
- The cognitive effects of ovariectomy and estrogen replacement are modulated by aging.Neuroscience. 2003; 119: 821-830
- Oxidative stress and inflammation in brain aging: nutritional considerations.Neurochem Res. 2005; 30: 927-935
- Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation.Behav Neurosci. 2002; 116: 902-911
- Estrogens, episodic memory, and Alzheimer's disease: a critical update.Semin Reprod Med. 2009; 27: 283-293
- Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.Ann Intern Med. 2002; 137: 149-155
- An 18-year follow-up of overweight and risk of Alzheimer disease.Arch Intern Med. 2003; 163: 1524-1528
- Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.Arch Neurol. 2004; 61: 661-666
- Midlife blood pressure and dementia: the Honolulu-Asia aging study.Neurobiol Aging. 2000; 21: 49-55
- Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.Ann Neurol. 2002; 52: 168-174
- Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.Curr Alzheimer Res. 2007; 4: 147-152
- The age-dependent relation of blood pressure to cognitive function and dementia.Lancet Neurol. 2005; 4: 487-499
- A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study.J Am Geriatr Soc. 2008; 56: 1449-1458
- Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.Neuroepidemiology. 1998; 17: 14-20
- Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans.Neurology. 2000; 54: 240-242
- APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.Neurology. 2005; 64: 1531-1538
- Body mass index in midlife and risk of Alzheimer disease and vascular dementia.Curr Alzheimer Res. 2007; 4: 103-109
- Midlife and late-life obesity and the risk of dementia: cardiovascular health study.Arch Neurol. 2009; 66: 336-342
- Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.Lancet neurology. 2006; 5: 735-741
- Association of diabetes mellitus and dementia: the Rotterdam Study.Diabetologia. 1996; 39: 1392-1397
- Hyperinsulinemia and risk of Alzheimer disease.Neurology. 2004; 63: 1187-1192
- Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study.Diabetes. 2009; 58: 71-77
- Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.Proc Natl Acad Sci USA. 2003; 100: 4162-4167
- Genomics of type 2 diabetes mellitus: implications for the clinician.Nat Rev Endocrinol. 2009; 5: 429-436
- Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study.Am J Prev Med. 2008; 35: 357-363
- Physical activity, diet, and risk of Alzheimer disease.JAMA. 2009; 302: 627-637
- Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies.Am J Geriatr Psychiatry. 2009; 17: 542-555
- Alcohol, dementia and cognitive decline in the elderly: a systematic review.Age Ageing. 2008; 37: 505-512
- Association between mid-life marital status and cognitive function in later life: population based cohort study.BMJ. 2009; 339: b2462
- An active and socially integrated lifestyle in late life might protect against dementia.Lancet Neurol. 2004; 3: 343-353
- Risk-reducing effect of education in Alzheimer's disease.Int J Geriatr Psychiatry. 2008; 23: 1156-1162
- Influence of education and occupation on the incidence of Alzheimer's disease.JAMA. 1994; 271: 1004-1010
- Education and the risk of Alzheimer's disease: findings from the study of dementia in Swedish twins.J Gerontol B Psychol Sci Soc Sci. 2001; 56: P292-300
- Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve.Brain. 2009; 132: 2036-2047
- Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.Ann Neurol. 2008; 63: 112-118
- Cognitive reserve.Neuropsychologia. 2009; 47: 2015-2028
- Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members.Proc Natl Acad Sci USA. 2001; 98: 3440-3445
- Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence.Psychol Med. 2009; 39: 3-11
- Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.JAMA. 2008; 300: 1027-1037
- Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease.Lancet Neurol. 2005; 4: 705-711
- Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins.J Gerontol A Biol Sci Med Sci. 2008; 63: 62-66
- Aerobic exercise enhances cognitive flexibility.J Clin Psychol Med Settings. 2009; 16: 186-193
- Cholinesterase inhibitors and beyond.Curr Alzheimer Res. 2009; 6: 86-96
- Memantine: a comprehensive review of safety and efficacy.Expert Opin Drug Saf. 2009; 8: 89-109
- Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium.CNS Neurosci Ther. 2009; 15: 333-344
- Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.Neurology. 2003; 61: 46-54
- A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.Nat Med. 2005; 11: 551-555
- A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.Aging Clin Exp Res. 2009; 21: 102-110
- Cognitive function over time in the Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.Arch Neurol. 2008; 65: 896-905
- Vitamin E and donepezil for the treatment of mild cognitive impairment.N Engl J Med. 2005; 352: 2379-2388
- Ginseng for cognitive function in Alzheimer's disease: a systematic review.J Alzheimers Dis. 2009; 18: 339-344
- Ginkgo biloba for prevention of dementia: a randomized controlled trial.JAMA. 2008; 300: 2253-2262
- Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.J Clin Psychopharmacol. 2008; 28: 110-113
- Neuropathologic substrate of mild cognitive impairment.Arch Neurol. 2006; 63: 38-46
- Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study.Neurobiol Aging. 2005; 26: 439-447
- Vitamin B-12, apolipoprotein E genotype, and cognitive performance in community-living older adults: evidence of a gene-micronutrient interaction.Am J Clin Nutr. 2009; 89: 1263-1268
- The effect of apolipoprotein E epsilon4 in the relationships of smoking and drinking to cognitive function.Neuroepidemiology. 1999; 18: 125-133
- Physical activity may modulate effects of ApoE genotype on lipid profile.Arterioscler Thromb Vasc Biol. 2002; 22: 133-140
- Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice.Hippocampus. 2007; 17: 1153-1157
- Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement.Neurology. 2006; 66: 35-40
- Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study.Stroke. 2001; 32: 2882-2889
- The association of APOE genotype and cognitive decline in interaction with risk factors in a 65–69 year old community sample.BMC Geriatr. 2008; 8: 14
- Projections of Alzheimer's disease in the United States and public health impact of delaying disease onset.Am J Public Health. 1998; 88: 1337-1342
- KEEPS: The Kronos Early Estrogen Prevention Study.Climacteric. 2005; 8: 3-12
Article info
Publication history
Published online: December 18, 2009
Accepted:
December 11,
2009
Received in revised form:
December 10,
2009
Received:
November 10,
2009
Identification
Copyright
© 2009 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
